Verana Health Enhances Bladder Cancer Database with Real-World Data Insights

Verana Health®, a leading digital health company, recently announced a major upgrade to its Real-World Data (RWD) bladder cancer database. This update is part of their ongoing commitment to enhancing patient care and bolstering clinical research in the field of genitourinary cancers.

The expanded database is rich in variables, presenting a comprehensive collection of longitudinal insights that researchers can leverage to analyze disease detection, treatment options, and patient outcomes. This development marks a significant step forward in understanding bladder cancer, a condition that affects many and poses serious health threats.

Sujay Jadhav, CEO of Verana Health, emphasized the profound impact that genitourinary cancers have not only on patients but also on their families. He remarked, “The effects are far-reaching, influencing not just the individual diagnosed but also their relatives and spouses.” With over 84,500 new bladder cancer cases expected in the U.S. this year alone, alongside nearly 18,000 resultant deaths, the need for improved data and insights becomes abundantly clear.

Recently, Verana Health has made significant investments to advance genitourinary cancer research, including establishing the world’s largest curated RWD prostate cancer dataset. The introduction of these datasets aligns with their vision to drive significant advancements in early detection, prompt treatment, and research aimed at improving patient outcomes.

As the exclusive data and analytics partner of the American Urological Association's (AUA) Quality (AQUA)® Registry, Verana Health is known for transforming unstructured urology data from electronic health records (EHRs) into high-quality research-ready datasets. Utilizing advanced technologies like artificial intelligence and large language models, Verana is setting new standards in the industry.

The upgraded bladder cancer database is designed to provide unique insights into treatment paradigms for both non-muscle invasive and muscle-invasive bladder cancers. This includes vital clinical data concerning T-stage classifications, tumor focality, tumor grades, and responses to treatments.

Moreover, the recent addition of data from participating urologists in the AQUA Registry, combined with Verana's merger with COTA, has expanded the company’s reach to over 30 Academic Medical Centers and more than 10 million assessable oncology patients. By aggregating this data across various specialties, Verana Health is creating an unparalleled view of the patient journey that is crucial for life sciences organizations seeking to generate evidence for regulatory submissions and make informed commercialization decisions.

This timely announcement coincides with the upcoming ASCO Annual Meeting, from May 29 to June 2 in Chicago, IL, which is the world’s largest oncology conference, expected to attract over 44,000 oncology professionals. Verana Health will likely highlight its newest developments and research capabilities fostering deeper connections with the scientific community.

To strengthen their research efforts, Verana is also linking disease-specific EHR data with additional resources, including genomics, medical claims, and imaging, thereby enhancing the insights available for researchers and clinicians.

In conclusion, the enhancements to Verana Health's bladder cancer database mark a significant advance towards fostering improved care strategies and outcomes for patients battling this challenging disease. As the company continues to innovate and evolve, it remains at the forefront of real-world evidence generation, ensuring that both patients and healthcare providers have access to the best available insights in the fight against cancer. For further information, visit www.veranahealth.com.